Xu Guang-Jun, Chen Tuan-Zhi, Jiang Gui-Sheng, Yao Lu-Su, Zhu Mei-Jia
Department of Neurology, Affiliated Qianfoshan Hospital of Shandong University Jinan, 66 Jingshi Road, Jinan 250014, Shandong Province, China ; Department of Neurology, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical College Liaocheng, China.
Department of Neurology, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical College Liaocheng, China.
Int J Clin Exp Med. 2015 Feb 15;8(2):2621-7. eCollection 2015.
This study is to explore and evaluate the efficacy and safety of local thrombolytic therapy in superior sagittal sinus in patients with severe cerebral venous sinus thrombosis during puerperium, as well as the efficacy and safety of anti-platelet aggregation treatment for preventing recurrence. Twelve patients during postpartum period with cerebral venous sinus thrombosis were received local thrombolytic therapy by placing a micro-catheter at the distal end of superior sagittal sinus from January 2008 to December 2013. All the patients accepted mechanical thrombus maceration before local intrasinus thrombolytic therapy, and were treated with low molecular weight heparin in the acute phase. After local thrombolytic therapy, anti-platelet aggregation treatment was performed for 6 months. Follow-up data included lumber puncture, fundus examination and magnetic resonance venography (MRV) once per half year for 6-70 months. At discharge, the intracranial pressure of 12 patients reduced to below 200 mmH2O. DSA or MRV confirmed that superior sagittal sinus of 9 patients were smooth. The cortex venous and deep venous were recovered to normal. Superior sagittal sinus of 3 patients recanalized partly. Cortex venous and deep venous was compensated. The follow-up study indicated that no thrombosis and new neurological symptoms occurred among all patients. Local thrombolytic treatment is safe and effective in patients with severe cerebral venous sinus thrombosis during puerperium. The collateral circulation compensation is the main recovery factor. And it is also safe and effective for anti-platelet aggregation treatment to prevent recurrence of cerebral venous sinus thrombosis.
本研究旨在探讨和评估局部溶栓治疗对产褥期严重脑静脉窦血栓形成患者上矢状窦的疗效和安全性,以及抗血小板聚集治疗预防复发的疗效和安全性。2008年1月至2013年12月,12例产后脑静脉窦血栓形成患者通过在上矢状窦远端放置微导管接受局部溶栓治疗。所有患者在局部窦内溶栓治疗前均接受机械性血栓溶解,并在急性期接受低分子量肝素治疗。局部溶栓治疗后,进行6个月的抗血小板聚集治疗。随访数据包括每半年进行一次腰椎穿刺、眼底检查和磁共振静脉血管造影(MRV),随访6 - 70个月。出院时,12例患者的颅内压降至200 mmHg2O以下。DSA或MRV证实9例患者的上矢状窦通畅,皮质静脉和深静脉恢复正常。3例患者的上矢状窦部分再通,皮质静脉和深静脉得到代偿。随访研究表明,所有患者均未出现血栓形成和新的神经症状。局部溶栓治疗对产褥期严重脑静脉窦血栓形成患者安全有效。侧支循环代偿是主要的恢复因素。抗血小板聚集治疗预防脑静脉窦血栓形成复发也安全有效。